Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
82°
Mostly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ardelyx Inc
(NQ:
ARDX
)
6.350
+0.300 (+4.96%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ardelyx Inc
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Ardelyx Posts Q4 Loss, Joins MercadoLibre, Booking Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session
February 23, 2024
U.S. stock futures were lower this morning, with the Dow futures trading lower by around 25 points on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Ardelyx Reports Mixed Q4 Results: Earnings Miss, Revenue Beat
February 22, 2024
Ardelyx reported quarterly losses of 12 cents per share which missed the analyst consensus estimate of losses of 10 cents by 20%. The company reported quarterly sales of $34.36 million, beating the...
Via
Benzinga
Topics
Earnings
Exposures
Financial
12 Health Care Stocks Moving In Thursday's After-Market Session
February 22, 2024
Via
Benzinga
Recap: Ardelyx Q4 Earnings
February 22, 2024
Via
Benzinga
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 22, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
How Is The Market Feeling About Ardelyx?
February 08, 2024
Via
Benzinga
Wedbush Maintains Outperform Rating for Ardelyx: Here's What You Need To Know
January 12, 2024
Via
Benzinga
Analyst Upgrades: 3 Stocks Predicted to Soar In Q2 2024
February 19, 2024
Pounce on the electric surge of analyst upgrades, guiding you through market uncertainties with considerable aplomb.
Via
InvestorPlace
3 Revolutionary Biotech Stocks Poised for 10X Surge
February 19, 2024
Discover three biotech stocks set to soar in a $3.08 trillion market, merging medical innovations with financial growth opportunities.
Via
InvestorPlace
3 Unstoppable Russell 2000 to Buy in February
February 08, 2024
These are a few companies that are within the Russell 2000 Index that offer investors great returns and a bright future.
Via
InvestorPlace
3 Sleeper Stocks Under $15 Ready to Explode by 2029
February 07, 2024
Discover 3 under-$15 stocks primed for a 2029 explosion, from fintech disruptors to biotech pioneers tackling untreatable rare diseases.
Via
InvestorPlace
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
February 06, 2024
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.
Via
InvestorPlace
Why Ardelyx Stock Is Climbing Higher
January 09, 2024
Via
Benzinga
What Analysts Are Saying About Ardelyx Stock
January 09, 2024
Via
Benzinga
What's Going On With Ardelyx Stock?
January 08, 2024
Ardelyx, Inc. (NASDAQ: ARDX) shares are trading higher Monday after the company provided a strategic business update.
Via
Benzinga
The 3 Best Biotech Stocks to Invest in for Big Gains in 2024
February 02, 2024
These pivotal biotech stocks for gains are charting the future of medicine and investment growth in 2024 offering powerful returns
Via
InvestorPlace
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
February 01, 2024
Conference call scheduled for 4:30 p.m. Eastern Time
From
Ardelyx, Inc.
Via
GlobeNewswire
3 Groundbreaking Biotech Stocks to Invest in Now
January 29, 2024
These are several biotech companies for investors seeking unique opportunities for great returns within the industry.
Via
InvestorPlace
7 Small-Cap Stocks to Buy for Big Gains in 2024
January 29, 2024
Small-cap stocks are a great way to diversify your portfolio and set yourself up for some potentially dynamic gains.
Via
InvestorPlace
3 mid-caps under $20 that Wall Street loves
January 23, 2024
MarketBeat's Stock Screener tool helped identify these three mid-cap stocks - with very bullish Wall Street sentiment - that are currently under $20 per share
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
Ardelyx, Inc. Reports Employment Inducement Grants
January 12, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
The 3 Best Under-$10 Stocks to Buy in January 2024
January 10, 2024
These are a few companies for investors looking for inexpensive options that still offer great earnings potential.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
January 09, 2024
Via
Benzinga
Nvidia, Boeing, Ardelyx, Crocs, Tesla: Why These 5 Stocks Are On Investors' Radars Today
January 08, 2024
Via
Benzinga
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 08, 2024
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on...
Via
Benzinga
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
January 08, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
January 03, 2024
Live event and webcast scheduled for 7:00 p.m. ET / 4:00 p.m. PT
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
December 20, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Positive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis Study
December 19, 2023
Aldeyra Therapeutics Inc (NASDAQ: ALDX) released topline results from a Phase 2 clinical trial of ADX-629, an investigational RASP modulator, in
Via
Benzinga
Patient Demand Drives Ardelyx's Constipation Drug Success Amid IBS-C Treatment Gap, Says Analyst
December 18, 2023
Raymond James initiated coverage of Ardelyx Inc (NASDAQ: ARDX), noting the company's two early-stage launches underway for the same molecule with differentiated pricing:
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.